GleamWall
中文EN

ANIX Anixa Biosciences Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 715446 · Fiscal year ends 10/31

Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.6%
TTM EPS YoY5.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-66.8%
ROA-63.4%
ROIC (approx.)-61.6%
Asset turnover—

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-18.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-07-312026Q22026-04-302026Q12026-01-312025Q4*2025-10-312025Q32025-07-312025Q22025-04-302025Q12025-01-312024Q4*2024-10-31
Income statement
Revenue————————
R&D expense$1.33M$1.26M$1.10M$1.14M$1.05M$1.32M$1.55M$1.48M
SG&A expense$1.41M$1.39M$1.61M$1.73M$1.38M$1.68M$1.83M$1.69M
Operating income-$2.74M-$2.65M-$2.72M-$2.88M-$2.44M-$3.00M-$3.39M-$3.16M
Net income-$2.61M-$2.52M-$2.56M-$2.69M-$2.26M-$2.79M-$3.18M-$2.88M
EPS (basic)-0.08-0.07-0.08—-0.07-0.09-0.10—
EPS (diluted)-0.08-0.07-0.08—-0.07-0.09-0.10—
Weighted avg. shares (diluted)34.18M33.59M33.24M—32.48M32.20M32.20M—
Balance sheet
Cash & equivalents$1.40M$1.48M$1.55M$1.24M$1.50M$1.91M$1.05M$1.27M
Short-term investments$12.47M$12.21M$12.65M$13.93M$14.53M$13.69M$16.20M$18.65M
Receivables—$56,000—————$173,000
Current assets$14.91M$14.69M$15.05M$15.89M$17.45M$16.77M$18.69M$21.36M
Total assets$15.07M$14.87M$15.23M$16.08M$17.65M$16.98M$18.91M$21.59M
Current liabilities$1.75M$1.50M$1.24M$1.97M$2.07M$1.89M$2.00M$2.50M
Total liabilities$1.87M$1.64M$1.39M$2.13M$2.24M$2.07M$2.19M$2.70M
Shareholders' equity$14.47M$14.47M$15.08M$15.16M$16.59M$16.07M$17.85M$20.00M
Shares outstanding34.58M33.92M33.46M33.01M32.82M32.21M32.20M32.20M
Cash flow statement
Operating cash flow-$1.77M-$1.74M-$2.61M-$1.25M-$1.51M-$1.50M-$2.90M-$927,000
Investing cash flow-$245,000$422,000$1.23M$654,000-$833,000$2.34M$2.70M$867,000
Financing cash flow$1.94M$1.25M$1.69M$350,000$1.93M$18,000-$17,000$106,000
Stock-based compensation$637,000$637,000$768,000$859,000$829,000$962,000$1.03M$980,000

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.